Neurozen
Gwangju, KR · 4 known investors
NeuroZen develops AI-based neuroimaging and genetic tools to predict, quantify, and monitor Alzheimer's disease and neurodegeneration, using multimodal clinical, neuropsychological, MRI, PET, and genomic data. Its products include AlzgenAI (genomic risk prediction), MemoAI (tablet-based cognitive testing), and NeuroAI (MRI/APOE-based amyloid PET positivity prediction), aimed at physicians for clinical decision-making, with a focus on Korean and Asian dementia cohorts.
Also known as NEUROZEN · Neurozen Co. · 뉴로젠
Founders & leadership
Investors · 4
Also in the syndicate · 3
Company profile
researched Aug 2026Neurozen (뉴로젠) develops deep learning-based neuroimaging and genetic solutions for risk assessment, early detection, quantification and monitoring of Alzheimer's disease and neurodegeneration. The company's stated aim is to give physicians clinical tools that support diagnostic and treatment decisions before irreversible brain damage or cognitive decline occurs. Its work draws on multimodal data spanning clinical, neuropsychological, MRI, PET and genomic inputs, with model training and validation carried out on a large Asian dementia cohort.
The product portfolio comprises AlzgenAI, a genomic risk-prediction service for identifying individuals at high risk of Alzheimer's disease based on Korean genome data; MemoAI, a tablet-based digitized visuospatial cognitive test with automated AI scoring; and NeuroAI, which predicts amyloid PET positivity from MRI and APOE genotype and is described as a Class 3 digital medical device. Additional services include Neuro I, a quantitative brain-image analysis system for assessing brain atrophy, NeuroAI as a clinical decision support system, and APOplus genetic testing. A third-party profile also lists genetic testing and Alzheimer's risk assessment services under the names NeuroXRP and NeuroXgen.
Founding story
The company was founded in 2015. A third-party profile names Sunny Lee and Kunho Lee as founding CEOs.
Business model
Neurozen supplies diagnostic and risk-assessment software and genetic testing services intended for use by physicians in clinical decision-making, spanning software-based imaging analysis (Neuro I, NeuroAI), tablet-based cognitive assessment (MemoAI) and laboratory genetic testing/risk scoring (APOplus, AlzgenAI).
Traction
Neurozen reports a Class 3 digital medical device designation for its NeuroAI amyloid PET positivity prediction product, and a third-party profile records a Series A raise in 2021.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Neurozen positions itself as a leader in dementia prediction technology, citing training and validation on what it describes as Asia's largest dementia cohort; a third-party profile states the company holds an exclusive license to the largest Asian dementia cohort organized by the National Research Center for Dementia (NRCD).
Neurozen cites access to a large Asian dementia cohort for AI training and validation, combined use of multimodal clinical, neuropsychological, MRI, PET and genomic data, a normative database for quantitative imaging comparison, and Korean population-specific genomic risk models.
Technology
The company applies deep learning to multimodal datasets combining clinical records, neuropsychological testing, MRI, PET imaging and genomic data. A normative reference database underpins quantitative comparison for brain atrophy assessment, and models predict amyloid PET positivity from MRI plus APOE genotype. Genomic risk prediction is built on Korean population genome data. Development involves a network of neuroscientists, radiologists, bioinformatics specialists and dementia experts.
Go-to-market
Physicians and clinical care teams involved in the assessment, diagnosis and monitoring of Alzheimer's disease and neurodegeneration, and individuals seeking Alzheimer's risk assessment through genetic testing.
Geography
Headquartered in Gwangju, South Korea, at 509-B, 193-12 Geumnam-ro, Dong-gu; a third-party profile lists a Seoul, South Korea location. Its data and models are oriented toward Korean and broader Asian dementia cohorts.
History
Founded in 2015, Neurozen built its product line around deep learning analysis of a large Asian dementia cohort, developing genomic (AlzgenAI, APOplus), cognitive (MemoAI) and imaging-based (Neuro I, NeuroAI) tools. A third-party profile records a KRW 3.1 billion Series A investment in 2021 with DT&Investment, Friend Investment Partners and iPlus Center listed as investors.
Compiled by commissioned research from 7 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 2
launches, deals, and filingsThird-party profile states Neurozen holds an exclusive license to the largest Asian dementia cohort organized by the National Research Center for Dementia (NRCD).
Company website lists NeuroAI, which predicts amyloid PET positivity from MRI and APOE genotype, as a Class 3 digital medical device.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 7
primary sources listed
- Neurozenneurozen.ai · web
7 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Neurozen do?
- Korean developer of AI-based neuroimaging and genetic tools for Alzheimer's disease risk assessment and early detection.
- Who are Neurozen's investors?
- Neurozen's investors include Colopl Next.
- Where is Neurozen headquartered?
- Neurozen is headquartered in Gwangju, KR.